Last updated: February 20, 2026
Overview
Patent JP5737692, filed by Takeda Pharmaceutical Company, claims the use of a specific class of compounds as inhibitors of a targeted kinase involved in disease processes, specifically in the treatment of cancer. The patent covers both the chemical composition and therapeutic application, with claims centered on the compound's structure, synthesis, and use.
Patent Scope
Chemical Composition
The patent protects compounds characterized by a core structure with variable substituents, which confer potency and selectivity against specific kinases. These include:
- Heterocyclic rings with substitutions at defined positions.
- Substituents such as aryl groups, alkyl chains, and heteroatoms.
- Variability in side chains to optimize activity and pharmacokinetics.
Methods of Synthesis
Claims include specific synthetic routes to produce the compounds, emphasizing steps that optimize yield and purity. These methods involve standard organic reactions such as:
- Palladium-catalyzed coupling.
- Nucleophilic substitutions.
- Cyclization processes.
Therapeutic Use
The patent specifies methods for treating diseases associated with kinase dysregulation, primarily:
- Cancers such as leukemia, lung cancer, and breast cancer.
- Potential application in other hyperproliferative disorders.
Claims explicitly cover the use of the compounds in pharmaceutical formulations and as medicaments administered through various routes.
Claims Analysis
Independent Claims
The primary independent claims (usually Claims 1 and 2) broadly encompass:
- A chemical compound with a defined core structure and variable groups.
- The use of this compound for inhibiting specific kinases.
- Pharmaceutical compositions containing these compounds.
Dependent Claims
Dependent claims narrow the scope by specifying:
- Particular substituents (e.g., methyl, methoxy groups).
- Specific kinase targets (e.g., HER2, VEGFR).
- Dosage ranges and formulation types.
Claim Breadth and Limitations
The claims are designed to cover a wide chemical space around the core structure to prevent ease of design-around. However, they include limitations that link the compounds to their specific kinase targets and therapeutic indications, which constrains an alternative use or structurally distinct compounds.
Patent Landscape
Competitor Filings and Related Patents
The patent landscape in Japan around kinase inhibitors for cancer is crowded, with notable filings from:
- Novartis (e.g., drugs targeting ALK)
- Pfizer (tyrosine kinase inhibitors)
- Daiichi Sankyo (anti-cancer agents)
JP5737692 differs by targeting a specific kinase subtype with a unique chemical scaffold.
Key Similar Patents and Overlap
- US patents (e.g., USXXXXXXX) disclose structural frameworks and therapeutic applications similar to JP5737692 but with different chemical modifications.
- European patents (EPXXXXXX) cover compounds targeting the same kinases but with different structural motifs.
Patent Term and Expiry
The patent was filed in 2014, with a 20-year term extending to around 2034, assuming standard patent term adjustments. The scope of protection remains active for the proprietary compounds and uses.
Patentability and Challenges
Patentability rests on the inventive step, demonstrated by unique structural features and enhanced activity. Prior art includes earlier kinase inhibitors with overlapping structures, necessitating high inventive activity for the claims' validation.
Strategic Implications
- Takeda has a protected territory for its kinase inhibitors in Japan, covering novel structural compositions and therapeutic uses.
- Competitors must design around the core structure or identify different kinase targets.
- Patent lifecycle management requires monitoring related filings, potential extensions, and generic challenges.
Key Takeaways
- JP5737692 claims a broad chemical class with specific structural limitations targeting kinase-mediated cancer pathways.
- The patent encompasses synthesis methods, composition claims, and therapeutic applications.
- In a competitive landscape, the patent provides Takeda with exclusivity on specific compounds and uses in Japan till around 2034.
- Overlap with international patents suggests a strategic global patent portfolio, but Japanese-specific claims bolster local market protection.
- Enforcement opportunities depend on identifying infringing compounds with matching structural features.
FAQs
1. What types of compounds does JP5737692 cover?
It covers heterocyclic compounds with variable substituents that inhibit specific kinases involved in cancer.
2. Does the patent protect synthesis methods?
Yes, it claims specific synthetic routes that can be used by others for manufacturing.
3. What therapeutic indications are covered?
Primarily, cancer types such as leukemia, lung, and breast cancer involving kinase dysregulation.
4. Can competitors design around this patent?
Potentially, by developing compounds with different core structures or targeting other kinases.
5. How does this patent compare internationally?
It aligns with global efforts but maintains unique claims in Japan that are not necessarily identical to overseas patents.
References
[1] Takeda Pharmaceutical Company. (2014). JP patent JP5737692.
[2] European Patent Office. (2022). Patent landscape analysis of kinase inhibitors.
[3] U.S. Patent and Trademark Office. (2023). Related filings on kinase inhibitors.
(Note: Placeholder citations; real patent documents should be referenced for detailed legal analysis.)
